Drug Profile
Moxifloxacin/dexamethasone
Alternative Names: AL-15469A/AL-38905; AL-15469A/AL-38905 ophthalmic formulation - Alcon Research; MoxiDex Otic; VIGADEXALatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class Anti-inflammatories; Aza compounds; Fluorinated steroids; Pregnadienetriols; Quinolines
- Mechanism of Action DNA gyrase inhibitors; Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular inflammation; Ophthalmic infections
- Discontinued Corneal disorders; Otitis externa; Otitis media
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon
- 05 Apr 2018 Novartis Pharmaceuticals in collaboration with Alcon Research plans a phase II trial for Otitis Externa (In children, In adolescents, In adults, In the elderly) in the US (EudraCT2018-000641-39)
- 24 Mar 2014 Alcon withdraws a phase III trial for Ocular inflammation and infection (prevention) in Brazil prior to enrolment (NCT01515826) (Ophthalmic, gel)